Zentalis Pharmaceuticals — Third Quarter 2026 Earnings Summary

Zentalis Pharmaceuticals reported third-quarter 2026 financial results showing $228.9 million in cash and marketable securities, providing a runway into the first half of 2028. The company's investigational WEE1 inhibitor, azenosertib, demonstrated meaningful overall survival data in the DENALI Part 1b trial for patients with Cyclin E1-positive platinum-resistant ovarian cancer. Enrollment for the DENALI Part 2c cohort is scheduled to complete in November 2026, with an integrated topline readout expected in the first half of 2027. Concurrently, the Phase 3 ASPENOVA trial continues to enroll patients globally to support a potential full approval pathway, while additional combination studies in ovarian cancer and triple-negative breast cancer are advancing.